Health Technology Assessment

OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland.

This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2018 conference in Vancouver, 1-5 June.

OHE’s Prof Nancy Devlin has been collaborating on a new approach to creating personal and social EQ-5D-5L value sets, based on a web application.

Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.

Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium.

A recently published editorial by OHE’s David Mott considers whether quantitative patient preference data has a role to play in HTA decision making.

A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the Task Force Report and pick up key points made in the various response articles. We also highlight further OHE work in this area.

A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.

Pages

Subscribe to RSS - Health Technology Assessment